Isavuconazole
drugOn this page
Also known as BAL-4815CresembaIsavuconazol
Summary
Isavuconazole (CHEMBL409153) is an approved small-molecule ergosterol biosynthesis inhibitor (ATC J02AC05); indicated across 6 conditions including aspergillosis and candidemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J02AC05
- Indications: 6 conditions
- Clinical trials: 39
- Chemistry: 437.5 Da · C22H17F2N5OS
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL409153 |
| Name | Isavuconazole |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 6918485 |
| ChEBI | CHEBI:85979 |
| ATC | J02AC05 |
| Molecular formula | C22H17F2N5OS |
| Molecular weight | 437.5 |
| InChIKey | DDFOUSQFMYRUQK-RCDICMHDSA-N |
SMILES: C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O
IUPAC name: 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
ChEBI definition: A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.
Pharmacological roles (ChEBI): ergosterol biosynthesis inhibitor, EC 1.14.13.70 (sterol 14α-demethylase) inhibitor, orphan drug.
Also known as: BAL-4815, Cresemba, Isavuconazol, Isavuconazole, isavuconazole, ISAVUCONAZOLE
Patent coverage: 760 distinct patent families (1,580 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,573 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Broad substrate specificity ATP-binding cassette transporter ABCG2.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| aspergillosis | 3 | MONDO:0005657 | EFO:0007157 |
| candidemia | 3 | MONDO:0044070 | EFO:1001282 |
| fungal infectious disease | 3 | MONDO:0002041 | MONDO:0002041 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 39.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 25 |
| Not specified | 5 |
| PHASE2 | 4 |
| PHASE3 | 3 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05630976 | PHASE4 | COMPLETED | Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi |
| NCT00412893 | PHASE3 | COMPLETED | Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis |
| NCT00413218 | PHASE3 | COMPLETED | Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections |
| NCT00413439 | PHASE2/PHASE3 | COMPLETED | Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy |
| NCT00634049 | PHASE3 | COMPLETED | Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi |
| NCT03964090 | PHASE2 | ACTIVE_NOT_RECRUITING | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) |
| NCT03019939 | PHASE2 | COMPLETED | Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia |
| NCT03149055 | PHASE2 | COMPLETED | Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) |
| NCT03327727 | PHASE2 | TERMINATED | VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults |
| NCT02203526 | PHASE1 | ACTIVE_NOT_RECRUITING | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma |
| NCT01406171 | PHASE1 | COMPLETED | Drug Interaction Study of Isavuconazole and Midazolam |
| NCT01494597 | PHASE1 | COMPLETED | Drug Interaction Study of Isavuconazole and Cyclosporine |
| NCT01535547 | PHASE1 | COMPLETED | Drug Interaction Study of Isavuconazole and Tacrolimus |
| NCT01555866 | PHASE1 | COMPLETED | Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole. |
| NCT01555918 | PHASE1 | COMPLETED | A Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers |
| NCT01565720 | PHASE1 | COMPLETED | Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization |
| NCT01582412 | PHASE1 | COMPLETED | Drug Interaction Study of Isavuconazole and Digoxin |
| NCT01582425 | PHASE1 | COMPLETED | Drug Interaction Study of Isavuconazole and Methadone |
| NCT01597986 | PHASE1 | COMPLETED | Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone |
| NCT01635946 | PHASE1 | COMPLETED | Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin |
| NCT01635972 | PHASE1 | COMPLETED | Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion |
| NCT01651325 | PHASE1 | COMPLETED | Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects |
| NCT01657825 | PHASE1 | COMPLETED | Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects |
| NCT01657838 | PHASE1 | COMPLETED | Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects |
| NCT01657890 | PHASE1 | COMPLETED | Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects |
| NCT01660477 | PHASE1 | COMPLETED | Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole |
| NCT01711489 | PHASE1 | COMPLETED | A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects |
| NCT01711827 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects |
| NCT01809860 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects |
| NCT01884558 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin |
| NCT01884636 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate |
| NCT02128321 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine |
| NCT02128893 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole |
| NCT05140096 | PHASE1 | COMPLETED | A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants |
| NCT06440915 | Not specified | RECRUITING | Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children |
| NCT07080359 | Not specified | NOT_YET_RECRUITING | Isavuconazole in Critically Ill Patients: Efficacy and Safety |
| NCT07185503 | Not specified | RECRUITING | Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety |
| NCT07191756 | Not specified | ACTIVE_NOT_RECRUITING | Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study |
| NCT04550936 | Not specified | COMPLETED | A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: aspergillosis, candidemia, fungal infectious disease